Service de Pneumologie & Oncologie Thoracique, Centre Hospitalier Universitaire de Caen, Caen, France.
Unicaen, UFR santé, Caen, France.
PLoS One. 2019 Sep 19;14(9):e0221211. doi: 10.1371/journal.pone.0221211. eCollection 2019.
BACKGROUND & AIMS: Pulmonary arterial hypertension is a severe disease associated with frequent hospitalisations. This retrospective analysis of the French medical information PMSI-MSO database aimed to describe incident cases of patients with pulmonary arterial hypertension hospitalised in France in 2013 and to document associated hospitalisation costs from the national health insurance perspective.
Cases of pulmonary arterial hypertension were identified using a diagnostic algorithm. All cases hospitalised in 2013 with no hospitalisation the previous two years were retained. All hospital stays during the year following the index hospitalisation were extracted, and classified as incident stays, monitoring stays or stays due to disease worsening. Costs were attributed from French national tariffs.
384 patients in France were hospitalised with incident pulmonary arterial hypertension in 2013. Over the following twelve months, patients made 1,271 stays related to pulmonary arterial hypertension (415 incident stays, 604 monitoring stays and 252 worsening stays). Mean age was 59.6 years and 241 (62.8%) patients were women. Liver disease and connective tissue diseases were documented in 62 patients (16.1%) each. Thirty-one patients (8.1%) died during hospitalisation and four (1.0%) received a lung/heart-lung transplantation. The total annual cost of these hospitalisations was € 3,640,382. € 2,985,936 was attributable to standard tariffs (82.0%), € 463,325 to additional ICU stays (12.7%) and € 191,118 to expensive drugs (5.2%). The mean cost/stay was € 2,864, ranging from € 1,282 for monitoring stays to € 7,285 for worsening stays.
Although pulmonary arterial hypertension is rare, it carries a high economic burden.
肺动脉高压是一种严重的疾病，常导致频繁住院。本项回顾性分析利用法国 PMSI-MSO 医疗信息数据库，旨在描述 2013 年法国新诊断肺动脉高压患者的住院病例，并从国家健康保险角度记录相关住院费用。
使用诊断算法确定肺动脉高压病例。保留 2013 年无前两年住院史的所有病例。提取索引住院后一年内在院的所有住院记录，并将其分类为新发病例住院、监测住院或因病情恶化住院。费用根据法国国家费率确定。
2013 年法国有 384 例肺动脉高压新发病例住院。在随后的 12 个月中，患者有 1271 例与肺动脉高压相关的住院（415 例新发病例住院、604 例监测住院和 252 例病情恶化住院）。患者平均年龄为 59.6 岁，241 例（62.8%）为女性。62 例（16.1%）患者存在肝脏疾病，62 例（16.1%）患者存在结缔组织疾病。31 例（8.1%）患者住院期间死亡，4 例（1.0%）患者接受了肺/心肺移植。这些住院的总年度费用为 3640382 欧元。2985936 欧元归因于标准费率（82.0%），463325 欧元归因于额外 ICU 住院（12.7%），191118 欧元归因于昂贵药物（5.2%）。平均每次住院费用为 2864 欧元，从监测住院的 1282 欧元到病情恶化住院的 7285 欧元不等。
尽管肺动脉高压罕见，但它带来了沉重的经济负担。
